REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Pakatan Harapan defeated Barisan Nasional in the 2018 general election. Concerns for a smooth power transition emerged as Najib declared that no party had achieved a majority. The National Palace of Malaysia subsequently confirmed Mahathir would be sworn in as Malaysia's seventh prime minister, refuting any claims of delaying the appointment. Immediately after the declaration of the results, people in Kuala Lumpur expressed their joy in celebration of the historic victory. Mahathir announced a two-day public holiday, adding: 'But there will be no holidays for the winners.' He became the world's oldest serving state leader (aged 92 years, 304 days at the time), and the first Malaysian prime minister not to represent UMNO. Mahathir was also officially recognized by Guinness World Records as the world's oldest serving prime minister. His deputy, Wan Azizah Wan Ismail became the first female deputy prime minister of Malaysia. In April 2019, Mahathir was listed among Time magazine's 100 most influential people.
Unlike most arbuscular mycorrhizal fungi, EcM fungi reproduce sexually and produce visible fruiting bodies in a wide variety of forms. The fruiting body, or sporocarp, can be thought of as an extension of the extraradical hyphae. Its cell walls and spores are typically composed of complex carbohydrates, and often incorporate a great deal of nitrogen. Many EcM fungi can only form fruiting bodies and complete their life cycles by participating in an EcM relationship. The fruit bodies of many species take on classic, well-recognized shapes such as epigeous mushrooms and hypogeous truffles. Most of these produce microscopic propagules of about 10 μm that can disperse over large distances by way of various vectors, ranging from wind to mycophagous animals. It has been suggested that animals are drawn to hypogeous fruiting bodies because they are rich in nutrients such as nitrogen, phosphorus, minerals and vitamins. However, others argue that the specific nutrients are less important than the availability of food at specific times of the year. Surveys of fruiting bodies have been used to assess community composition and richness in many studies. However, this method is imperfect as fruiting bodies do not last long and can be hard to detect.
== Effects on global climate == In climate change science, ENSO is known as one of the internal climate variability phenomena. The other two main ones are Pacific decadal oscillation and Atlantic multidecadal oscillation. La Niña impacts the global climate and disrupts normal weather patterns, which can lead to intense storms in some places and droughts in others. El Niño events cause short-term (approximately 1 year in length) spikes in global average surface temperature while La Niña events cause short term cooling. Therefore, the relative frequency of El Niño compared to La Niña events can affect global temperature trends on decadal timescales.
Sources: en.wikipedia.org
Adropin is a small protein composed of 76 amino acids, and it is produced primarily in the liver and the brain. The precursor of adropin is a larger protein called Energy Homeostasis-Associated (ENHO), and adropin is released through the cleavage of ENHO.
Corticotropin-releasing hormone (CRH), which regulates ACTH secretion from the anterior pituitary gland Somatostatin, which regulates growth hormone secretion from the anterior pituitary gland Thyrotropin-releasing hormone (TRH), which regulates TSH and prolactin secretion
== Synthesis of nucleotides == Nucleotides are the monomers that polymerize to form nucleic acids. Each nucleotide consists of a sugar, a phosphate group, and a nitrogenous base. The nitrogenous bases found in nucleic acids belong to one of two categories: purines or pyrimidines. In complex multicellular animals, both purines and pyrimidines are primarily synthesized in the liver, but they follow distinct biosynthetic pathways. However, all nucleotide synthesis requires phosphoribosyl pyrophosphate (PRPP), which donates the ribose and phosphate needed to form a nucleotide.
=== January === 1 January – In his New Year address, Archbishop of Canterbury Justin Welby urges politicians to treat their opponents as human beings rather than enemies. Secretary of State for Defence Grant Shapps says that British forces are ready to act against Houthi rebels targeting cargo ships in the Red Sea. Writing on X, Doug Barrowman, husband of Michelle, Baroness Mone, said it "suits the agenda" of ministers to "scapegoat" him and his wife as a means of distracting from government "incompetence" at failing to procure personal protective equipment during the COVID-19 pandemic. 2 January – The Home Office says it has fulfilled a pledge to clear a "legacy" backlog of 92,000 asylum applications lodged before July 2022. But after it subsequently emerges that over 4,000 cases are still waiting for a decision, the Office for Statistics Regulation (OSR) announces an examination of the figures the next day. 3 January – Sir Ed Davey, leader of the Liberal Democrats, launches the party's election campaign by targeting constituencies with Conservative MPs. Former chancellor of the exchequer Nadhim Zahawi makes a guest appearance in the ITV drama Mr Bates vs The Post Office as himself, questioning Post Office chief executive Paula Vennells in a 2015 House of Commons committee inquiry into the Horizon computer system. Richard Tice, leader of Reform UK, rules out a pact with the Conservative Party at the next general election. 4 January – Prime Minister Rishi Sunak says his "working assumption" is that the general election will take place in the second half of this year.
Sources: en.wikipedia.org
Stained brain slice images which include the "Hypothalamus" at the BrainMaps project The Hypothalamus and Pituitary at endotexts.org NIF Search - Hypothalamus via the Neuroscience Information Framework Space-filling and cross-sectional diagrams of hypothalamic nuclei: right hypothalamus, anterior, tubular, posterior.
July 4, 2014: France ratifies the Council of Europe Convention on preventing and combating violence against women and domestic violence (known as the "Istanbul Convention"). August 4, 2014: Law for real equality between women and men (in public, professional, and private spheres). September 11, 2014: Decree on the responsibilities of the Minister for Social Affairs, Health, and Women's Rights. October 1, 2014: Decree on responsibilities delegated to the Secretary of State for Women's Rights. October 15, 2014: Health bill proposing that school nurses may provide emergency contraception and midwives may offer medical abortions. December 29, 2014: Public finance programming law for 2014–2019, with provisions concerning family allowances. January 16, 2015: National action program to improve access to abortion. March 2015: The High Council for Gender Equality publishes a scientific study on violence against women in public transportation and recommends a national action plan. August 17, 2015: Law on social dialogue and employment, including provisions against sexist behavior. October 15, 2015: Ordinance simplifying and modernizing family law. December 21 or 23, 2015: Decree on approving information centers on women's and family rights. December 21 or 23, 2015: Social Security Financing Law for 2016, including measures to guarantee unpaid child support. January 26, 2016: Health system modernization law; the minimum 7-day reflection period for abortion is abolished; midwives may offer medical abortions; health centers may perform surgical abortions.
In the Roman Catholic Church, the full-fingered gloves traditionally worn by the pope or other bishops are also known as gauntlets or episcopal gloves, though their use has largely been relaxed since Paul VI.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.